Compare AJANTA PHARMA with Fulford India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs FULFORD INDIA - Comparison Results

FULFORD INDIA 
   Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA FULFORD INDIA AJANTA PHARMA/
FULFORD INDIA
 
P/E (TTM) x 27.5 398.8 6.9% View Chart
P/BV x 6.8 6.2 109.3% View Chart
Dividend Yield % 0.5 0.1 612.9%  

Financials

 AJANTA PHARMA   FULFORD INDIA
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-19
FULFORD INDIA
Mar-14
AJANTA PHARMA/
FULFORD INDIA
5-Yr Chart
Click to enlarge
High Rs1,422942 150.9%   
Low Rs898450 199.5%   
Sales per share (Unadj.) Rs233.5691.4 33.8%  
Earnings per share (Unadj.) Rs44.011.5 383.6%  
Cash flow per share (Unadj.) Rs52.215.4 339.6%  
Dividends per share (Unadj.) Rs9.002.00 450.0%  
Dividend yield (eoy) %0.80.3 270.1%  
Book value per share (Unadj.) Rs255.1380.0 67.1%  
Shares outstanding (eoy) m88.023.90 2,256.9%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x5.01.0 493.4%   
Avg P/E ratio x26.460.7 43.4%  
P/CF ratio (eoy) x22.245.3 49.1%  
Price / Book Value ratio x4.51.8 248.2%  
Dividend payout %20.517.4 117.3%   
Avg Mkt Cap Rs m102,0812,714 3,760.7%   
No. of employees `0006.80.4 1,531.5%   
Total wages/salary Rs m4,307505 852.9%   
Avg. sales/employee Rs Th3,022.66,073.0 49.8%   
Avg. wages/employee Rs Th633.41,137.4 55.7%   
Avg. net profit/employee Rs Th569.1100.7 565.3%   
INCOME DATA
Net Sales Rs m20,5542,696 762.3%  
Other income Rs m211125 168.1%   
Total revenues Rs m20,7652,822 735.9%   
Gross profit Rs m5,664-46 -12,207.5%  
Depreciation Rs m72115 4,742.1%   
Interest Rs m1210 122.1%   
Profit before tax Rs m5,14354 9,470.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,27310 13,260.4%   
Profit after tax Rs m3,87045 8,657.0%  
Gross profit margin %27.6-1.7 -1,601.5%  
Effective tax rate %24.817.7 140.0%   
Net profit margin %18.81.7 1,135.7%  
BALANCE SHEET DATA
Current assets Rs m11,8121,738 679.5%   
Current liabilities Rs m3,776545 693.3%   
Net working cap to sales %39.144.3 88.3%  
Current ratio x3.13.2 98.0%  
Inventory Days Days7748 159.7%  
Debtors Days Days824 1,895.5%  
Net fixed assets Rs m14,39812 120,995.0%   
Share capital Rs m17539 449.7%   
"Free" reserves Rs m22,2771,443 1,543.8%   
Net worth Rs m22,4521,482 1,515.0%   
Long term debt Rs m70-   
Total assets Rs m26,9622,077 1,298.3%  
Interest coverage x444.36.7 6,616.3%   
Debt to equity ratio x00-  
Sales to assets ratio x0.81.3 58.7%   
Return on assets %14.42.6 551.6%  
Return on equity %17.23.0 571.4%  
Return on capital %23.04.3 533.1%  
Exports to sales %00-   
Imports to sales %024.5 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA659 0.0%   
Fx inflow Rs m10,68217 62,102.9%   
Fx outflow Rs m2,102673 312.2%   
Net fx Rs m8,580-656 -1,308.0%   
CASH FLOW
From Operations Rs m3,74890 4,164.2%  
From Investments Rs m-2,228105 -2,130.0%  
From Financial Activity Rs m-1,475-14 10,458.2%  
Net Cashflow Rs m45181 25.0%  

Share Holding

Indian Promoters % 73.8 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 1.6 3.8 40.8%  
FIIs % 7.6 0.1 7,600.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 21.2 80.2%  
Shareholders   20,968 4,783 438.4%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  ALEMBIC  ALKEM LABORATORIES  ELDER PHARMA  

Compare AJANTA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

5 Reasons Why Sensex and Nifty Plunged 2% Today(Closing)

Indian share markets witnessed heavy selling pressure today despite the US administration saying it would bring a stimulus package even without the opposition's support.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 46.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 46.3% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 28.9% (Quarterly Result Update)

Aug 24, 2020 | Updated on Aug 24, 2020

For the quarter ended June 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 7 bn (up 9.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 45.3% (Quarterly Result Update)

May 21, 2020 | Updated on May 21, 2020

For the quarter ended March 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 45.3% YoY). Sales on the other hand came in at Rs 7 bn (up 32.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 60.8% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 60.8% YoY). Sales on the other hand came in at Rs 7 bn (up 34.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (2QFY20); Net Profit Down 7.2% (Quarterly Result Update)

Nov 8, 2019 | Updated on Nov 8, 2019

For the quarter ended September 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (down 7.2% YoY). Sales on the other hand came in at Rs 6 bn (up 18.1% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

One Chart to See Before You Sell(Fast Profits Daily)

Jan 22, 2021

In this video, I'll show you a crucial chart that you need to check before you decide to sell any stock or index.

Invest in the Multibaggers of 2021 and Beyond(Profit Hunter)

Jan 21, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Jan 27, 2021 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 5-YR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS